[Frontiers in Bioscience 2, d283-293, June 1, 1997]
Reprints
PubMed
CAVEAT LECTOR



Table of Conents
 Previous Section   Next Section

INHIBITION OF THE HIV REV TRANSACTIVATOR: A NEW TARGET FOR THERAPEUTIC INTERVENTION
Adriana Heguy

Oncogene Science, Inc., 106 Charles Lindbergh Blvd., Uniondale, NY 11553

Received 6/2/97; Accepted 6/4/97

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. Rev structure and function
3.1 Rev domains
3.2 Rev-RRE interactions
3.3 Cellular factors that interact with Rev
3.4 Mechanism of action of Rev
4. Rev as target for therapeutic intervention
4.1 Rev as a target for gene therapy
4.1.1 Protein-based suppressors of Rev function
4.1.2 Intracellular expression of RNA-based Rev inhibitors
4.2 Inhibiting Rev function via antisense oligonucleotides and other nucleic-acid molecules
4.3 Low-molecular weight compounds and natural products that inhibit Rev
4.3.1 Intercalating agents and other RNA-binding compounds
4.3.2 Screening approaches
5. Conclusions and Perspective
6. Acknowledgments
7. References
8. Entire manuscript

Keywords:HIV, AIDS, Therapy, Immune System, Rev transactivator

Search OMIM (Online Mendelian Inheritance in Man) to find related articles
This form requires a WWW Client such as Netscape, XMosaic, Lynx that supports fill-in forms.

Enter one or more search keywords:

To Search all fields, leave the following boxes unchecked. To narrow your search to certain specific fields, check the boxes next to those fields' names. SeeQuery Help for other ways to search. Title: OMIM Number: Allelic Variants: Text: References: Clinical Synopsis: Gene Map Disorder: Contributors: See only records which have been changed in the past Display at most